Video Latest - ecancer

ITACA NSCLC study: Final results

Prof Silvia Novello - University of Turin, Turin, Italy

16 Feb 2021

KEYNOTE-598: pembrolizumab with ipilimumab or placebo in patients with untreated metastatic NSCLC

Prof Michael Boyer - Chris O’Brien Lifehouse, Sydney, Australia

16 Feb 2021

TALAPRO-1: phase II study of talazoparib in patients with DNA damage repair alterations and mCRPC

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

15 Feb 2021

ASCO GU 2021: Renal cancer roundup

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

15 Feb 2021

OncoAlert and ecancer weekly roundup for February 07 - 13, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

15 Feb 2021

OncoAlert and ecancer weekly roundup for February 01 - 06, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

9 Feb 2021

Latest in EGFR-positive NSCLC with exon 20 insertion mutations

Prof Sanjay Popat, Prof Michael Thomas, Dr Marina Garassino, Dr Rosario Campelo, Dr Enriqueta Felip

9 Feb 2021

WCLC 2020 overview

Dr Luis Raez - Memorial Healthcare System, Hollywood, FL, USA

5 Feb 2021

Emergence of PARP inhibitors in prostate cancer

Kenrick Ng - Senior Specialist Registrar in Medical Oncology, UCL Hospitals, London, UK

5 Feb 2021

Advances and treatment strategies for metastatic hormone-sensitive prostate cancer

Kenrick Ng - Senior Specialist Registrar in Medical Oncology, UCL Hospitals, London, UK

5 Feb 2021

OncoAlert and ecancer weekly roundup for January 25 - 31, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

4 Feb 2021

Role of PARP inhibitors in treating advanced prostate cancer

Noam Shabani - Dana-Farber Cancer Institute, Boston, USA

3 Feb 2021

Video